Institutional members access full text with Ovid®

Share this article on:

Lymphocyte Subpopulations and Interleukin Levels in High-Risk Melanoma Patients Treated With High-Dose Interferon A-2B

Gogas, Helen M.D.; Paterakis, George M.D.; Frangia, Konstantina M.D.; Bafaloukos, Dimitrios M.D.; Pectasides, Dimitrios M.D.; Kalofonos, Haralambos P. M.D.; Loukopoulos, Dimitrios M.D.; Stavropoulou-Giokas, Cathrin M.D.; Ioannovich, John M.D.; Mihm, Martin C. Jr. M.D., F.A.C.P.

American Journal of Clinical Oncology: December 2002 - Volume 25 - Issue 6 - p 591-596

Immunologic effects of high-dose interferon are still unclear. We have evaluated changes in blood lymphocyte subpopulations, immunoglobulins, and multiple interleukin in patients with high-risk cutaneous melanoma on adjuvant treatment with high-dose interferon and compared pretreatment values with normal controls. Samples were obtained before treatment, 1 month after induction treatment and at 3, 6, and 12 months of maintenance treatment from 24 patients with high-risk melanoma. Lymphocyte subpopulations were measured by flow cytometry and interleukin and immunoglobulin levels by radioimmunoassay. A statistically significant reduction in B-lymphocytes (p < 0.001), natural killer (NK) cells (p = 0.0004), and monocytes (p = 0.04), and an elevation in CD4/CD8 ratio (p < 0.0001) was observed after 1 month of intravenous interferon. No changes were seen in CD3, CD4, and CD8 lymphocytes. No changes in interleukin (IL)-2, -4, or -5 were observed during 1 year of treatment. IL-2 pretreatment levels were significantly lower than healthy blood donors (p = 0.001), and IL-5 pretreatment levels were significantly higher (p = 0.0056). IL-10 levels significantly dropped after 6 months of treatment (p = 0.01). Immunoglobulins (IgG, IgA, IgM) remained within normal ranges. Three patients had elevated pretreatment levels of IgE. There is a time- and dose-dependent impact of interferon on numbers of circulating B lymphocytes, NK cells, monocytes, and CD4/CD8 ratio. Defects in cellular and humoral immunity are suggested by the low IL-2 and high IL-5 levels, measured in patients with melanoma as compared with healthy controls.

From the 1st Department of Internal Medicine, Athens University, “Laiko” Hospital (H.G., D.B., D.P., H.P.K., D.L.); Department of Immunology and National Tissue Typing Center, General Hospital of Athens (G.P., C.S.-G.); Pathology Department (K.F.) and Department of Plastic Surgery and Microsurgery, General Hospital of Athens “G. Gennimatas” (J.I.), Athens, Greece; and Department of Dermatopathology, Massachusetts General Hospital (M.C.M.), Boston, Massachusetts, U.S.A.

Address correspondence and reprint requests to Dr. Helen Gogas, P.O. Box 14120, Athens 115 10 Greece.

© 2002 Lippincott Williams & Wilkins, Inc.